Methods and compositions relating to anti-interleukin-4 receptor antibodies
Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.
1. An isolated anti-IL4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO:10.
2. An isolated anti-IL4 receptor antibody comprising a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 12.
3. An isolated anti-IL4 receptor antibody comprising a light-chain variable region comprising the amino acid sequence of SEQ ID NO:10 and a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 12.
4. An isolated antibody, wherein the light chain CDR 3 comprises the sequence of residues 90–99 of SEQ ID NO:10, the heavy chain CDR 3 comprises the sequence of residues 98–104 of SEQ ID NO:12, and said antibody binds to the human IL-4 receptor.
5. The isolated antibody of claim 4 , wherein the light chain CDR 1 comprises the sequence of residues 24–35 of SEQ ID NO:10 and the heavy chain CDR 1 comprises the sequence of residues 31–35 of SEQ ID NO:12.
6. The isolated antibody of claim 4 , wherein the light chain CDR 2 comprises the sequence of residues 51–57 of SEQ ID NO:10 and the heavy chain CDR 2 comprises the sequence of residues 50–65 of SEQ ID NO:12.
7. The isolated antibody of claim 4 , wherein the light chain CDR 1 comprises the sequence of residues 24–35 of SEQ ID NO:10, the heavy chain CDR 1 comprises the sequence of residues 31–35 of SEQ ID NO:12, the light chain CDR 2 comprises the sequence of residues 51–57 of SEQ ID NO:10, and the heavy chain CDR 2 comprises the sequence of residues 50–65 of SEQ ID NO:12.
8. The isolated antibody of claim 4 , wherein the light chain variable region comprises the sequence of SEQ ID NO:10.
9. The isolated antibody of claim 4 , wherein the heavy chain variable region comprises the sequence of SEQ ID NO:12.
10. The isolated antibody of claim 4 , wherein the light chain variable region comprises the sequence of SEQ ID NO:10 and the heavy chain variable region comprises the sequence of SEQ ID NO:12.
11. The isolated antibody of claim 4 , wherein said antibody is a monoclonal antibody.
12. The isolated antibody of claim 4 , wherein said antibody is human, partially human, or chimeric.
13. The isolated antibody of claim 4 wherein said antibody is an IgA antibody, an IgD antibody, an IgE antibody, an IgG antibody, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, an IgG4 antibody, or an IgM antibody.
14. A fragment of the antibody of claim 4 , wherein said fragment comprises the sequence of residues 90–99 of SEQ ID NO:10, the sequence of residues 98–104 of SEQ ID NO:12, and binds to human IL-4 receptor.
15. The antibody fragment of claim 14 , wherein said fragment further comprises an Fc domain or a leucine zipper.
16. The antibody fragment of claim 14 , wherein said fragment comprises a Fab fragment or a F(ab′)2 fragment.
17. The antibody fragment of claim 14 , wherein said fragment is part of a single chain antibody (scFv).